2021-05-17T11:55:58-05:00 2020-06-30 ERNST & YOUNG US LLP 4365 EXECUTIVE DR STE 1600 SAN DIEGO CA 92121 990 2019-07-01 510197108 SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE % LOUIS COFFMAN SANF 8586463100 10901 NORTH TORREY PINES ROAD LA JOLLA CA 92037 LOUIS COFFMAN CAO & CFO 8586463100 2021-05-17 true JOCELYNE MILLER P00634378 8585357200 2019 2022-09-23 18:48:47Z C RANDAL MILLS PHD 10901 NORTH TORREY PINES ROAD LA JOLLA CA 92037 330130622 false X WWW.SBPDISCOVERY.ORG X 1976 CA SEE SCHEDULE O 17 16 779 19 2023074 0 108300329 100963692 799803 643286 11593574 12481799 2262753 2641626 122956459 116730403 0 0 0 0 65811734 62755446 0 0 1437805 120469124 49892483 186280858 112647929 -63324399 4082474 338796799 307274683 123189379 93150241 215607420 214124442 X SEE SCHEDULE O false false 92098609 0 757474 SEE SCHEDULE O 92098609 true true false true false false false false false true true true false false false true true false false true true false false false true false false false false true true false false false false false false false false false false true false false false false false false false false true 183 0 true 779 true true true false false false false true true false false false false false false X 17 16 false false false false false false false true true false false true true true true true true true true false AL AK AR CA CO CT DC FL GA IL KS KY ME MD MA MI MN MS NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI X LOUIS COFFMAN 8586463100 10901 NORTH TORREY PINES RD LA JOLLA CA 92037 KRISTIINA VUORI MD PHD PRESIDENT 50.0 0.0 X X 1022617 0 350424 GARTH POWIS PHD CENTER DIRECTOR 50.0 0.0 X 504532 0 53042 MICHAEL JACKSON PHD DRUG DISCOVERY & DEV, SR VP 50.0 1.0 X 432356 0 58766 CARL WARE PHD CENTER DIRECTOR, IIDC 50.0 1.0 X 437966 0 52965 JORGE MOSCAT PHD PROGRAM DIRECTOR 50.0 1.0 X 431058 0 55855 LOUIS COFFMAN CAO & CFO 50.0 0.0 X 434723 0 40656 ZE'EV RONAI PHD PROGRAM DIRECTOR 50.0 0.0 X 383277 0 65401 DOUGLAS OBENSHAIN TRUSTEE 1.0 0.0 X 0 0 0 DAVID DOWN TRUSTEE 1.0 0.0 X 0 0 0 WILLIAM GERHART VICE CHAIRMAN 1.0 0.0 X X 0 0 0 STUART TANZ TRUSTEE 1.0 0.0 X 0 0 0 JAMES JARDON TRUSTEE 1.0 0.0 X 0 0 0 JAMES MYERS TRUSTEE 1.0 0.0 X 0 0 0 KAZUMI SHIOSAKI PHD TRUSTEE 1.0 0.0 X 0 0 0 PETER SEIDLER TRUSTEE (PART YEAR) 1.0 0.0 X 0 0 0 DAN EPSTEIN TRUSTEE 1.0 0.0 X 0 0 0 WILLIAM ROPER TRUSTEE 1.0 0.0 X 0 0 0 MATTHEW BROWNE TRUSTEE 1.0 0.0 X 0 0 0 DAVID SZEKERES TRUSTEE 1.0 0.0 X 0 0 0 KAREN HAYNES PHD TRUSTEE 1.0 0.0 X 0 0 0 DONALD KERNS PHD TRUSTEE 1.0 0.0 X 0 0 0 JEANNE HERBERGER TRUSTEE (PART YEAR) 1.0 0.0 X 0 0 0 ANNA BARKER PHD TRUSTEE 1.0 0.0 X 0 0 0 HENRY NORDOFF TRUSTEE 1.0 0.0 X 0 0 0 JAMES BLAIR PHD CHAIRMAN 1.0 0.0 X X 0 0 0 KNOX BELL CORPORATE SECRETARY 2.0 0.0 X 0 0 0 3646529 0 677109 119 false true false DELOITTE TOUCHE LLP 655 WEST BROADWAY SUITE 400 SAN DIEGO CA 92101 AUDIT SERVICES 384891 WILSON SONSINI GOODRICH PO BOX 742866 LOS ANGELES CA 90074 LEGAL SERVICES 258150 STEALTH PARTNER GROUP 18940 NORTH PIMA ROAD SUITE 210 SCOTTSDALE AZ 85255 ADMIN SERVICES 190745 DLA PIPER LLP PO BOX 64029 BALTIMORE MD 21264 LEGAL SERVICES 180078 CLARIVATE ANALYTICS LLC PO BOX 3772 CAROL STREAM IL 60132 DATA CONSULTANTS 178713 7 307815 65458505 35197372 55580 100963692 SHARED SERVICES REVENUE 541990 643286 643286 0 0 643286 3446814 3446814 0 0 577664 577664 59600 59600 0 59600 59600 222275304 213240319 9034985 9034985 9034985 27000 307815 159900 -132900 -132900 0 0 0 0 0 0 Research 541700 2023074 0 2023074 0 OTHER RESEARCH SUPPORT 541990 55844 55844 0 0 SALE OF REAGENTS 541990 28844 28844 0 0 29500 29500 0 2137262 116730403 757474 2023074 12986163 0 0 0 0 0 0 0 0 1732086 154502 1577584 0 0 0 0 0 47298550 37613090 8872115 813345 3233587 2496251 681134 56202 7516566 5939878 1480539 96149 2974657 2241787 680054 52816 1193907 152805 947216 93886 481077 38648 442429 0 348063 0 348063 0 1500 0 1500 0 0 0 628171 0 628171 0 904054 634330 264443 5281 12502 0 12502 0 5649705 4967362 631083 51260 1250113 920349 299493 30271 0 0 0 0 10985009 10013170 903696 68143 298833 261466 35489 1878 0 0 0 0 928370 672391 247820 8159 1778605 1622088 145490 11027 0 0 0 0 7050756 6430289 576752 43715 184870 0 184870 0 RESEARCH SUPPLIES & SVCS 9195443 9195443 0 0 Scientific collaborations 8532168 8532168 0 0 TUITION FEES 116358 116358 0 0 BAD DEBT 58322 0 58322 0 294657 96234 92750 105673 112647929 92098609 19111515 1437805 0 8780651 8063493 2469 3899 11771097 5921294 470995 416137 0 0 0 0 377300 189635 45516 18229 7961896 8256177 162944495 109551937 57111231 53392558 218451769 202465901 33823875 28547360 0 0 0 0 0 0 338796799 307274683 15973902 12191460 0 0 52727813 30022951 54487664 50935830 0 0 0 0 0 0 0 0 0 0 123189379 93150241 X 184566051 184924802 31041369 29199640 215607420 214124442 338796799 307274683 4082474 -5565452 0 0 X false true X true true true X 112703072 121777889 113630164 108300329 100963692 557375146 0 0 112703072 121777889 113630164 108300329 100963692 557375146 17224174 540150972 5532193 6303751 5346565 5942288 3455907 26580704 52137 281883 48551 0 0 382571 0 584338421 7895918 0.92438 0.87030 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED false false false 0 false 0 false 0 false 0 false 0 false 0 true 1500 1500 false SCHEDULE C, PART II-B, LINE 1I DUES TO A RESEARCH AND BIOMEDICAL ORGANIZATION, A PORTION OF WHICH IS CONSIDERED LOBBYING. 20562387 1005 724999 1373539 19914852 29799743 4000 1337873 1327075 29814541 28681314 502000 1841686 1225257 29799743 25987641 530336 3395420 1232083 28681314 26693919 510067 -3125 1213220 25987641 0.00000 0.70550 0.29450 false false 12758161 12758161 87265126 56520257 30744869 62276941 53031680 9245261 644267 0 644267 53392558 PRIVATE EQUITY LPS 3378883 F TOTAL RETURN HEDGE FUNDS 8343174 F SELECT EQUITY FUNDS 16825303 F 28547360 0 0 X 110538000 -5565452 -5565452 116103452 628171 -1220 626951 116730403 112020000 112020000 628171 -242 627929 112647929 SCHEDULE D, PART V, LINE 4 INTENDED USES OF THE ORGANIZATION'S ENDOWMENT FUNDS THE INSTITUTE'S ENDOWMENT FUNDS ARE ESTABLISHED FOR VARIOUS PURPOSES: SCIENTIFIC RESEARCH, CEO CHAIR, PRESIDENTIAL CHAIR, CANCER AND NEUROSCIENCE LEADERSHIP CHAIRS, AND UNRESTRICTED AS TO INCOME. SCHEDULE D, PART V, LINE 1A FY20 ENDOWMENT BEGINNING BALANCE THE BOARD DESIGNATED ENDOWMENTS OF $9,252,154 WAS REMOVED FROM THE BEGINNING BALANCE ENDOWMENT TOTAL IN ACCORDANCE WITH THE FORM 990 INSTRUCTIONS. SCHEDULE D, PART X, LINE 2 FIN 48 (ASC 740) FOOTNOTE THE INSTITUTE HAS NO MATERIAL DEFERRED TAX ASSETS OR DEFERRED TAX LIABILITIES RECORDED AS OF JUNE 30, 2020 AND 2019. THE INSTITUTE DID NOT RECOGNIZE A CHANGE IN LIABILITY FOR UNRECOGNIZED TAX BENEFITS (THE DIFFERENCE BETWEEN A TAX POSITION TAKEN, OR EXPECTED TO BE TAKEN, IN A TAX RETURN AND THE BENEFIT RECOGNIZED AND MEASURED IN THE FINANCIAL STATEMENTS). THERE WERE NO LIABILITIES FOR UNRECOGNIZED TAX BENEFITS AT JUNE 30, 2020 AND 2019. SCHEDULE D, PART XI, LINE 4B ROUNDING - ($1,220) SCHEDULE D, PART XII, LINE 4B ROUNDING - ($242) Europe (Including Iceland and Greenland) 0 24 Program Services SEE PART V 79753 East Asia and the Pacific 0 1 Program Services SEE PART V 9401 South Asia 0 3 Program Services SEE PART V 7929 Central America and the Caribbean 0 4 Program Services SEE PART V 3128 North America 0 1 Program Services SEE PART V 1741 Central America and the Caribbean 0 0 Investments 10842516 0 33 0 33 10944468 10944468 true false true true true false SCHEDULE F, PART I, LINE 3 PROGRAM SERVICE ACTIVITIES SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE DOES NOT MAINTAIN ONGOING OPERATIONS IN FOREIGN JURISDICTIONS. HOWEVER, THE INSTITUTE'S SCIENTIST DO TRAVEL TO VARIOUS SCIENTIFIC CONFERENCES IN OTHER COUNTRIES TO SHARE THE INSTITUTE'S SCIENTIFIC DISCOVERIES, AS WELL AS, TO LEARN FROM OTHER SCIENTISTS ACROSS THE WORLD. SCHEDULE F, PART I, LINE 3, COLUMN E TYPE OF SERVICE SPECIFIC PROGRAM SERVICE ACTIVITY IN ALL REGIONS IS AGENTS ATTENDING AND/OR SPEAKING AT SCIENTIFIC CONFERENCES AND COLLABORATIONS. SCHEDULE F, PART I, LINE 3, COLUMN F ACCOUNTING METHOD THE ACCRUAL METHOD OF ACCOUNTING WAS USED TO DETERMINE THE AMOUNTS IN PART I, LINE 3, COLUMN F. ED GILLENWATERS CONSULTING false BLAIR BLUM PARTNERS CONSULTING false GALA 334815 307815 27000 54589 37987 67324 0 334815 307815 27000 54589 37987 67324 159900 -132900 X X true true X X X X X X false true false false false false false true false KRISTIINA VUORI MD PHD PRESIDENT 770603 0 250000 0 2014 0 328000 0 22424 0 1373041 0 0 0 GARTH POWIS PHD CENTER DIRECTOR 448552 0 50000 0 5980 0 28000 0 25042 0 557574 0 0 0 CARL WARE PHD CENTER DIRECTOR, IIDC 394063 0 38940 0 4963 0 28000 0 24965 0 490931 0 0 0 LOUIS COFFMAN CAO & CFO 379609 0 50000 0 5114 0 14063 0 26593 0 475379 0 0 0 MICHAEL JACKSON PHD DRUG DISCOVERY & DEV, SR VP 408973 0 20289 0 3094 0 28000 0 30766 0 491122 0 0 0 ZE'EV RONAI PHD PROGRAM DIRECTOR 344715 0 34204 0 4358 0 28000 0 37401 0 448678 0 0 0 JORGE MOSCAT PHD PROGRAM DIRECTOR 409194 0 17528 0 4336 0 28000 0 27855 0 486913 0 0 0 FORM 990, SCHEDULE J, PART I, LINE 1A FIRST CLASS TRAVEL FIRST CLASS TRAVEL IS GENERALLY NOT PERMITTED, EXCEPT UNDER VERY LIMITED AND RARE CIRCUMSTANCES AND CONDITIONS, SUCH AS A MEDICAL CONDITION REQUIREMENT AND URGENT CIRCUMSTANCES. THIS WAS NOT TREATED AS TAXABLE COMPENSATION. HEALTH OR SOCIAL CLUB DUES HEALTH OR SOCIAL CLUB DUES ARE NEGOTIATED IN THE HIRING PROCESS FOR CERTAIN EMPLOYEES. THE AMOUNTS WERE TREATED AS TAXABLE COMPENSATION. FORM 990, SCHEDULE J, PART I, LINE 4B SUPPLEMENTAL NONQUALIFIED RETIREMENT PLAN THE PARTICIPANT OF THE 457(F) DEFERRED COMPENSATION PLAN IS KRISTIINA VUORI. VESTING OCCURS THE EARLIEST OF 04/01/20, OR INVOLUNTARY TERMINATION WITHOUT CAUSE, OR PARTICIPANT'S RESIGNATION FOR GOOD CAUSE, OR THE DATE OF TERMINATION OF THE PLAN. DISTRIBUTION IS A ONE-TIME LUMP SUM PAYMENT UPON VESTING OF 100% OF THE VALUE OF THE PARTICIPANT'S INVESTMENT (COMPRISED OF INSTITUTE CONTRIBUTIONS TO THE CORPUS PLUS ANY INVESTMENT GAINS OR LOSSES THEREON). THE AMOUNTS VESTED WERE INCLUDED IN CALENDAR YEAR 2020 COMPENSATION WILL BE REPORTED ACCORDINGLY ON THE 2020 FORM 990. FORM 990, SCHEDULE J, PART I, LINE 7 NON FIXED PAYMENTS SOME SENIOR EXECUTIVES HAVE EMPLOYMENT AGREEMENTS STIPULATING A BONUS WILL BE PAID TO THEM PROVIDED CERTAIN GOALS OR ACCOMPLISHMENTS ARE ACHIEVED. A COUNTY OF SAN DIEGO 956000934 79742YAQ5 2015-11-12 61963256 SEE PART VI false false false A 0 15643870 61963256 0 0 46030000 289386 0 0 0 0 0 2015 true false true true A false true true true true true 0.01450 0.01450 false false false true A false true false false true false 0 false 0 false true A true SCHEDULE K, PART I, ROW A, COLUMN (F) REFINANCE 2006 AND 2012 BONDS WITH ISSUE DATES OF 02/01/2006 AND 11/15/2012, RESPECTIVELY. SCHEDULE K, PART I, ROW A FOR THE BOND ISSUES LISTED IN PART I, THE ALTERNATIVE PERIOD USED FOR THE REPORTING REQUIREMENTS IN THIS SECTION IS THE TWELVE MONTHS ENDED DECEMBER 31, 2019. X hand sanitizer, gal. 36 2580 FMV X surgical masks 57400 53000 FMV false false false FORM 990, SCHEDULE M, PART I, LINE 25, COLUMN (B) COLUMN B IS REPORTING A COMBINATION OF THE NUMBER OF CONTRIBUTIONS RECEIVED AND THE NUMBER OF ITEMS RECEIVED. FORM 990 , PART I, LINE 1 & PART III, LINE 1 ORGANIZATIONS MISSION SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE CONDUCTS WORLD-CLASS, COLLABORATIVE RESEARCH DEDICATED TO FINDING CURES FOR HUMAN DISEASE, IMPROVING THE QUALITY OF LIFE, AND THUS CREATING A LEGACY FOR ITS EMPLOYEES, PARTNERS, DONORS, AND COMMUNITY. FORM 990, PART III, LINE 4 SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE (SBP) IS AN INDEPENDENT NONPROFIT MEDICAL RESEARCH ORGANIZATION THAT DEDICATED TO UNCOVERING THE ORIGINS OF DISEASE AND LAUNCHING BOLD NEW STRATEGIES LAYING THE FOUNDATION FOR CURES. OUR INSTITUTE HAS DEEP EXPERTISE IN FUNDAMENTAL BIOLOGY AND ONE OF THE MOST COMPREHENSIVE DRUG DISCOVERY CENTERS IN THE NONPROFIT WORLD. CANCER MICROFLUID DEVICE CAPTURES CIRCULATING TUMOR CELL CLUSTERS: NEARLY 90% OF CANCER DEATHS ARE DUE TO METASTASES, WHEN TUMORS SPREAD THROUGHOUT THE BODY. TO HELP SCIENTISTS STUDY THIS PROCESS, RESEARCHERS FROM SANFORD BURNHAM PREBYS, SAN DIEGO STATE UNIVERSITY AND TUMORGEN MDX INC. CREATED A MICROFLUIDIC DEVICE THAT CAPTURES CIRCULATING CANCER CELL CLUSTERS. THE TECHNOLOGY WAS DESCRIBED IN AIP ADVANCES. DIGESTION-AIDING HERBS ALTER GUT MICROBIOME: A STUDY PUBLISHED BY SANFORD BURNHAM PREBYS AND UC SAN DIEGO SCIENTISTS IN EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE FOUND THAT DIGESTION-AIDING HERBS PROMOTED STRONG SHIFTS IN GUT BACTERIA KNOWN TO REGULATE METABOLISM. THIS INSIGHT MAY LEAD TO TREATMENTS FOR COLON CANCER, AUTOIMMUNE CONDITIONS AND MORE SERIOUS DISEASES. PREBIOTICS HELP FIGHT MELANOMA BY ACTIVATING ANTI-TUMOR IMMUNITY: TWO PREBIOTICS-NUTRIENTS THAT FEED THE FRIENDLY BACTERIA IN THE GUT-SLOWED THE GROWTH OF MELANOMA IN MICE BY BOOSTING THE IMMUNE SYSTEMS ABILITY TO FIGHT CANCER. THE STUDY, LED BY ZEEV RONAI, PH.D., PROVIDES FURTHER EVIDENCE THAT GUT MICROBES PLAY A ROLE IN SHAPING THE IMMUNE RESPONSE TO CANCER, AND SUPPORTS EFFORTS TO TARGET THE GUT MICROBIOME TO ENHANCE THE EFFICACY OF CANCER THERAPY. (CELL REPORTS) PANCREATIC CANCER BLOCKED BY DISRUPTING CELLULAR PH BALANCE: A NEW STUDY BY COSIMO COMMISSO, PH.D., ILLUSTRATES THE POTENTIAL TO TARGET CELLULAR PH-A MEASURE OF ACIDITY-AS AN APPROACH TO COMBATING PANCREATIC CANCER. BY SUPPRESSING SPECIFIC PROTEINS, THE RESEARCH TEAM WAS ABLE TO DISRUPT THE ACIDIC PH THAT CANCER CELLS USE TO SUPPORT THEIR METABOLISM. THE TEAMS NEXT STEP IS TO WORK WITH OUR DRUG DISCOVERY TEAM IN THE PREBYS CENTER TO FIND DRUGS THAT SEQUESTER ACID AND COMPROMISE PANCREATIC CELL GROWTH. (CANCER DISCOVERY) ONE-TWO PUNCH DRUG COMBINATION OFFERS HOPE FOR PANCREATIC CANCER: PANCREATIC CANCER IS ONE OF THE DEADLIEST FORMS OF CANCER-FEWER THAN 10 PERCENT OF PEOPLE REMAIN ALIVE FIVE YEARS AFTER DIAGNOSIS. ZE'EV RONAI, PH.D., IDENTIFIED A COMBINATION OF TWO FDA-APPROVED DRUGS THAT SHRANK PANCREATIC TUMORS IN MICE. THE DRUGS ARE CURRENTLY USED TO TREAT CERTAIN LEUKEMIAS AND SOLID TUMORS. THE RESEARCH SUPPORTS THE IMMEDIATE EVALUATION OF THE DRUG COMBINATION IN CLINICAL TRIALS FOR PANCREATIC CANCER. (NATURE CELL BIOLOGY) NEW SURVIVAL STRATEGY FOR OXYGEN-STARVED PANCREATIC CANCER CELLS: BY BLOCKING PANCREATIC CANCERS OXYGEN-SENSING MACHINERY-THE SAME FIELD OF RESEARCH STUDIED BY THE WINNERS OF THE 2019 NOBEL PRIZE IN MEDICINE-OUR SCIENTISTS HAVE UNCOVERED A PREVIOUSLY UNKNOWN TECHNIQUE TUMORS USE TO SPROUT BLOOD VESSELS, CALLED ANGIOGENESIS. THE DISCOVERY, PUBLISHED IN CANCER RESEARCH, COULD LEAD TO A TREATMENT THAT IS GIVEN WITH AN ANTI-ANGIOGENETIC MEDICINE AND OVERCOMES DRUG RESISTANCE. BOOSTING THE IMMUNE SYSTEM'S ABILITY TO FIGHT CANCER: CANCER IMMUNOTHERAPIES HAVE REVOLUTIONIZED THE TREATMENT OF CERTAIN CANCERS, BUT THEY DON'T WORK FOR EVERYONE. ZE'EV RONAI, PH.D., HAS SHOWN THAT THE SIAH2 PROTEIN HELPS CONTROL IMMUNE CELLS CALLED T REGULATORY CELLS, WHICH LIMIT THE EFFECTIVENESS OF IMMUNOTHERAPIES. THE RESEARCH, WHICH OFFERS A NEW WAY TO PURSUE IMMUNOTHERAPY IN CASES WHERE THE TREATMENT FAILS, WAS PUBLISHED IN NATURE COMMUNICATIONS. IMMUNOTHERAPY COMBINATION ERADICATES PEDIATRIC BRAIN CANCER: WHEN IMMUNOTHERAPY WORKS, IT CAN BE LIFE-CHANGING. BUT IT DOESN'T WORK FOR EVERYONE OR EVERY CANCER. NOW ROBERT WECHSLER-REYA, PH.D., HAS SHOWN THAT COMBINING IMMUNOTHERAPY WITH A DRUG CALLED TUMOR NECROSIS FACTOR ERADICATES A DEADLY PEDIATRIC BRAIN TUMOR IN MICE. THE DISCOVERY, PUBLISHED IN NATURE NEUROSCIENCE, IS EXPECTED TO LEAD TO A CLINICAL TRIAL FOR CHILDREN FIGHTING BRAIN CANCER. PREVENTING PANCREATIC CANCER METASTASIS BY KEEPING CELLS "SHELTERED IN PLACE": COSIMO COMMISSO, PH.D., HAS SHOWN THAT PANCREATIC CANCER METASTASIS-WHEN TUMOR CELLS GAIN THE ABILITY TO MIGRATE TO NEW PARTS OF THE BODY-CAN BE SUPPRESSED BY INHIBITING A PROTEIN THAT REGULATES CELL MOVEMENT, CALLED SLUG. THE STUDY, PUBLISHED IN THE JOURNAL OF EXPERIMENTAL MEDICINE, ALSO REVEALED TWO DRUGGABLE TARGETS THAT COULD LEAD TO TREATMENTS THAT STOP THE SPREAD OF PANCREATIC CANCER. DEGENERATIVE DISEASES ANTIMICROBIAL PROTEIN IMPLICATED IN PARKINSON'S DISEASE: AN IMMUNE SYSTEM PROTEIN THAT TYPICALLY PROTECTS THE BODY FROM PATHOGENS IS ABNORMALLY PRODUCED IN THE BRAIN DURING PARKINSON'S DISEASE, SCIENTISTS FROM SANFORD BURNHAM PREBYS REPORT. THE DISCOVERY, PUBLISHED IN FREE RADICAL BIOLOGY & MEDICINE, INDICATES THAT DEVELOPING A DRUG THAT BLOCKS THIS PROTEIN, CALLED MYELOPEROXIDASE, MAY HELP PEOPLE WITH PARKINSON'S DISEASE. PROTECTING PREMATURE BABIES FROM A COMMON BRAIN DISORDER: PREMATURE BABIES HAVE DELICATE BRAIN TISSUE THAT IS PRONE TO BLEEDING AND POST-HEMORRHAGIC HYDROCEPHALUS, A DANGEROUS CONDITION THAT LEADS TO EXCESS FLUID AND BRAIN DYSFUNCTION. JEROLD CHUN M.D., PH.D., LED A STUDY THAT OPENS NEW AVENUES TO PURSUE COMMERCIALLY AVAILABLE COMPOUNDS THAT PREVENT EXCESS FLUID FROM ACCUMULATING IN THE BRAINS OF PREMATURE INFANTS. (SCIENCE ADVANCES) DEVELOPMENT, AGING AND REGENERATION AN EARLY SIGN OF TYPE 2 DIABETES: MISFOLDED PROINSULIN: MISFOLDED PROINSULIN-A PROTEIN THE BODY NORMALLY PROCESSES INTO INSULIN-IS AN EARLY SIGN OF TYPE 2 DIABETES, ACCORDING TO A STUDY BY RANDAL KAUFMAN, PH.D. THE DISCOVERY COULD LEAD TO TESTS OR TREATMENTS THAT HELP PREVENT MORE THAN 80 MILLION AMERICANS WITH PREDIABETES FROM DEVELOPING FULL-BLOWN TYPE 2 DIABETES. THE STUDY WAS PUBLISHED IN ELIFE. MACHINE LEARNINGS NEXT FRONTIER: EPIGENETIC DRUG DISCOVERY: MACHINE LEARNINGS POWERFUL ABILITY TO DETECT PATTERNS IN COMPLEX DATA IS REVOLUTIONIZING HOW WE DRIVE CARS, DIAGNOSE DISEASE, AND NOW HOW WE DISCOVER NEW DRUGS. ALEXEY TERSKIKH, PH.D., HAS DEVELOPED A MACHINE LEARNING ALGORITHM THAT GLEANS INFORMATION FROM MICROSCOPIC DNA IMAGES-ALLOWING FOR A NEW TYPE OF HIGH-THROUGHPUT DRUG SCREENS THAT PROVIDE INSIGHTS INTO CANCER, HEART DISEASE, MENTAL ILLNESS AND OTHER HEALTH CONDITIONS. (ELIFE) A DEEP DIVE INTO CELL AGING: AN FDA-APPROVED DRUG THAT HELPED SUPPRESS THE DAMAGING EFFECTS OF CELL AGING WAS DESCRIBED IN A NEW STUDY BY PETER ADAMS, PH.D. THE RESEARCH, PERFORMED IN MICE, EXAMINED HOW AGING CELLS ENTER A SLEEP-LIKE STATE OF AGING CALLED SENESCENCE. THE STUDY IDENTIFIED A DRUG, CURRENTLY USED TO TREAT CERTAIN CANCERS, THAT TRANSFORMED SENESCENT CELLS FROM A LARGE AND FLAT FORM TO A VISUALLY YOUTHFUL CONDITION. THE TEAM PLANS TO WORK WITH THE PREBYS CENTER TO SCREEN FOR LESS TOXIC VERSIONS OF THE DRUG. (GENES & DEVELOPMENT) LONG-SOUGHT PROTEIN STRUCTURE OFFERS NEW APPROACH TO TREATING DISEASE: FRANCESCA MARASSI, PH.D., LED A COLLABORATION THAT SOLVED THE STRUCTURE OF AN ESSENTIAL BLOOD PROTEIN: VITRONECTIN. KNOWING THE PROTEIN'S STRUCTURE MAY ADVANCE OUR UNDERSTANDING OF A BROAD RANGE OF CONDITIONS INCLUDING MULTI-DRUG-RESISTANT INFECTIONS, CANCER METASTASIS, AGE-RELATED MACULAR DEGENERATION AND MORE. (SCIENCE ADVANCES) MRI PREDICTS EFFICACY OF STEM CELL THERAPY FOR BRAIN INJURY: TOOLS THAT PREDICT THE EFFICACY OF NEURAL STEM CELL THERAPY COULD INCREASE THE SUCCESS OF CLINICAL TRIALS, WHICH ARE ONGOING IN PEOPLE WITH PARKINSON'S DISEASE, SPINAL CORD INJURY AND OTHER NEUROLOGICAL CONDITIONS. EVAN SNYDER, M.D., PH.D., SUCCESSFULLY USED MRI TECHNOLOGY TO PREDICT OUTCOMES IN ANIMAL MODELS OF NEURAL INJURY. HE IS NOW PLANNING A CLINICAL TRIAL FOR BABIES BORN WITH A SPECIFIC TYPE OF BIRTH-RELATED BRAIN INJURY. (CELL REPORTS) THE SECRET TO A LONG LIFE? FOR WORMS, A CELLULAR RECYCLING PROTEIN IS KEY: NEW RESEARCH, LED BY MALENE HANSEN, PH.D., DISCOVERED THAT EXCESS LEVELS OF A SPECIFIC PROTEIN HELPS WORMS LIVE LONGER. THE PROTEIN RECOGNIZES AND DESTROYS TOXIC PROTEINS TO KEEP CELLS HEALTHY. THE FINDINGS OPEN NEW RESEARCH OPPORTUNITIES FOR AGE-RELATED CONDITIONS SUCH AS ALZHEIMER'S DISEASE, WHICH ARE OFTEN CAUSED BY THE ACCUMULATION OF MISFOLDED, HARMFUL PROTEINS. (NATURE COMMUNICATIONS) DNA SHAPE MAKES A BIG DIFFERENCE IN YOUR HEALTH: PIER LORENZO PURI, M.D., HAS USED A CUTTING-EDGE GENOMIC TECHNOLOGY TO SHOW THAT MYOD-A MASTER REGULATOR OF MUSCLE DEVELOPMENT-CAN ALTER THE GENOME'S ARCHITECTURE AND DETERMINE IF DNA MUTATIONS ARE EXPRESSED OR HIDDEN. THE STUDY, PUBLISHED IN MOLECULAR CELL, HELPS EXPLAIN WHY PATIENTS WITH THE SAME MUTATION CAN HAVE DIFFERENT DISEASE PROGRESSION AND SYMPTOMS. RESEARCH UNCOVERS GENETIC MUTATIONS LINKED TO AUTISM SPECTRUM DISORDER: SCIENTISTS AT SANFORD BURNHAM PREBYS AND RADBOUD UNIVERSITY MEDICAL CENTER IN THE NETHERLANDS HAVE IDENTIFIED MUTATIONS IN A GENE CALLED CNOT1 THAT AFFECT BRAIN DEVELOPMENT AND IMPAIR MEMORY AND LEARNING. THE RESEARCH, PUBLISHED IN THE AMERICAN JOURNAL OF HUMAN GENETICS, ALSO REVEALED THAT CNOT1 INTERACTS WITH SEVERAL KNOWN AUTISM SPECTRUM DISORDER GENES, OPENING NEW RESEARCH AVENUES FOR THE CONDITION. POTENTIAL DRUG TARGET FOR TYPE 2 DIABETES REVEALED BY MAPPING PROINSULINS "SOCIAL NETWORK": FOR THE FIRST TIME, SANFORD BURNHAM PREBYS SCIENTISTS HAVE MAPPED THE VAST NETWORK OF PROTEINS THAT INTERACT WITH PROINSULIN, THE PROTEIN THE BODY NORMALLY PROCESSES INTO INSULIN. THE STUDY, PUBLISHED IN DIABETES, REVEALED ONE PROTEIN-CALLED PRDX4-THAT MAY BE ESSENTIAL FOR PROINSULIN FOLDING AND INSULIN PRODUCTION. THE RESEARCH SUGGESTS THAT BOOSTING PRDX4 LEVELS MAY IMPROVE THE HEALTH OF PEOPLE WITH DIABETES. HUMAN GENETICS ADVANCING STEM CELL THERAPIES FOR BRAIN INJURY: EVAN SNYDER, M.D., PH.D., TEAMED UP WITH SCIENTISTS AT LOMA LINDA UNIVERSITY HEALTH TO DEMONSTRATE THE PROMISE OF USING MAGNETIC RESONANCE IMAGING (MRI) TO HELP PREDICT THE EFFICACY OF STEM CELL TREATMENTS FOR NEUROLOGICAL DISORDERS. THE RESEARCHERS ARE PLANNING A CLINICAL TRIAL FOR NEWBORNS WHO EXPERIENCE A BIRTH-RELATED BRAIN INJURY. THE STUDY WAS PUBLISHED IN CELL REPORTS. FIRST SUPERCENTENARIAN IPSCS CREATED: EVAN SNYDER, M.D., PH.D., HAS SUCCESSFULLY REPROGRAMMED CELLS FROM A 114-YEAR-OLD WOMAN INTO INDUCED PLURIPOTENT STEM CELLS (IPSCS). NOW, STUDIES CAN BEGIN TO REVEAL THE "SECRET SAUCE" OF SUPERCENTENARIANS-WHO LIVE REMARKABLY LONG AND HEALTHY LIVES. THE STUDY WAS PUBLISHED IN BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. NEW TEST FOR RARE DISEASE IDENTIFIES CHILDREN WHO MAY BENEFIT FROM SIMPLE SUPPLEMENT: HUDSON FREEZE, PH.D., TEAMED WITH SCIENTISTS AT THE CENTRO DE BIOLOGA MOLECULAR SEVERO OCHOA IN SPAIN TO CREATE A TEST THAT DETERMINES WHICH CHILDREN WITH CAD DEFICIENCY-A RARE METABOLIC DISEASE-ARE LIKELY TO BENEFIT FROM RECEIVING URIDINE, A NUTRITIONAL SUPPLEMENT THAT CAN DRAMATICALLY IMPROVE THE LIVES OF CHILDREN WITH THE CONDITION. THE STUDY WAS PUBLISHED IN GENETICS IN MEDICINE. IMMUNITY AND PATHOGENESIS FOUR DRUGS HOLD NEAR-TERM PROMISE TO FIGHT COVID-19: SUMIT CHANDA, PH.D., LED AN INTERNATIONAL COLLABORATION THAT SCREENED MORE THAN 12,000 EXISTING DRUGS FOR ACTIVITY AGAINST SARS-COV-2, THE VIRUS THAT CAUSES COVID-19. FOUR OF THE DRUGS WERE ABLE TO STOP THE VIRUS FROM REPLICATING AT DOSES LIKELY TO BE EFFECTIVE AND TOLERABLE IN HUMANS. THE RESEARCH INCREASES THE NUMBER OF "SHOTS ON GOAL" FOR A POTENTIAL TREATMENT AND COULD REACH PATIENTS FASTER THAN DRUGS CREATED FROM SCRATCH. (BIORXIV) NEW DRUG CANDIDATE REAWAKENS SLEEPING HIV IN HOPES OF A CURE: SANFORD BURNHAM PREBYS SCIENTISTS HAVE DESIGNED A NEXT-GENERATION DRUG CALLED CIAPAVIR THAT IS EFFECTIVE AT REACTIVATING DORMANT HUMAN IMMUNODEFICIENCY VIRUS (HIV). THE RESEARCH, PUBLISHED IN CELL REPORTS MEDICINE, AIMS TO CREATE A FUNCTIONAL HIV CURE USING A "SHOCK AND KILL" APPROACH THAT FIRST ACTIVATES AND THEN ELIMINATES ALL POCKETS OF DORMANT HIV. FORM 990, PART VI, LINE 11B PROCESS USED BY MANAGEMENT AND/OR GOVERNING BODY TO REVIEW FORM 990 THE 990 IS PREPARED BY THE FINANCE DEPARTMENT. IT IS REVIEWED BY THE INSTITUTE'S TAX ADVISORS, SELECTED MEMBERS OF MANAGEMENT INCLUDING THE CFO AND AUDIT COMMITTEE, AND PROVIDED TO MEMBERS OF THE BOARD PRIOR TO FILING. FORM 990, PART VI, LINE 12C DESCRIPTION OF PROCESS TO MONITOR TRANSACTIONS FOR CONFLICT OF INTEREST SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE HAS A CONFLICT OF INTEREST POLICY THAT REQUIRES ALL TRUSTEES, PRINCIPAL OFFICERS OR MEMBERS OF A COMMITTEE WITH BOARD DELEGATED POWERS TO ANNUALLY CONFIRM THEIR RECEIPT OF THE CONFLICT OF INTEREST POLICY AND DISCLOSE ANY NEW ASSOCIATIONS OR INTERESTS THAT MIGHT POTENTIALLY POSE A CONFLICT. THIS IS A WRITTEN CONFIRMATION THAT SHE OR HE READ AND UNDERSTANDS THE CONFLICT OF INTEREST POLICY, WILL ABIDE BY THE CONFLICT OF INTEREST POLICY AND CERTIFIES DISCLOSURE OF ALL INTERESTS OR RELATIONSHIPS THAT MAY POSE CONFLICTS. IN ADDITION, EACH YEAR NEW TRUSTEES RECEIVE TRAINING REGARDING THE INSTITUTES CONFLICT OF INTEREST POLICY, WHICH INCLUDES HOW TO IDENTIFY A CONFLICT OF INTEREST AND HOW TO HANDLE POSSIBLE CONFLICTS OF INTEREST WHEN THEY ARISE. THE COMPLIANCE DEPARTMENT REVIEWS EACH OF THE STATEMENTS AND ASSESSES WHETHER AN ACTUAL OR POTENTIAL CONFLICT OF INTEREST EXISTS/MAY EXIST AND WHETHER THE INDIVIDUAL SHOULD BE PROHIBITED FROM CONSIDERATION OF RELATED ITEMS. ANY TRUSTEE, PRINCIPAL OFFICER OR MEMBER OF A COMMITTEE WITH BOARD DELEGATED POWERS WITH A CONFLICT IN A MATTER REQUIRING ACTION BY THE BOARD ARE PROHIBITED FROM PARTICIPATING IN THE BOARDS DELIBERATIONS AND/OR VOTING ON THE PARTICULAR TRANSACTION OR MATTER IN WHICH HE OR SHE HAS AN INTEREST; AND OTHERWISE REFRAIN FROM EXERTING ANY INFLUENCE TO AFFECT A DECISION. HOWEVER, OTHER MEASURES MAY BE REQUIRED, DEPENDING ON THE NATURE OF AND THE ABILITY TO REASONABLY MANAGE A CONFLICT. FORM 990, PART VI, LINES 15A & 15B PROCESS FOR DETERMINING COMPENSATION COMPENSATION FOR THE CEO, THE PRESIDENT, CHIEF FINANCIAL OFFICER, AND OTHER KEY EMPLOYEES IS ESTABLISHED ACCORDING TO INSTITUTE POLICIES WHICH ARE DESIGNED TO MEET THE IRS STANDARD FOR "REBUTTABLE PRESUMPTION OF REASONABLENESS". THE COMPENSATION COMMITTEE OF THE BOARD OF TRUSTEES, CONSISTING OF FOUR INDEPENDENT TRUSTEES, REVIEWS COMPARABILITY DATA PROVIDED BY AN INDEPENDENT EXTERNAL CONSULTANT THAT INCORPORATES AND EVALUATES INSTITUTE DATA AND THAT OF COMPARABLE ORGANIZATIONS AND MARKETS FROM WHICH THE INSTITUTE DRAWS ITS EXECUTIVE TALENT. UTILIZING THIS INFORMATION, THE COMPENSATION COMMITTEE, WHICH TYPICALLY SEEKS TO ESTABLISH COMPENSATION BETWEEN THE 50TH AND THE 75TH PERCENTILE OF THE COMPARABILITY DATA, MAKES A DETERMINATION WHETHER THE PROPOSED COMPENSATION IS REASONABLE. THE COMPENSATION COMMITTEE HAS BEEN DELEGATED AUTHORITY BY THE BOARD OF TRUSTEES TO REVIEW AND APPROVE COMPENSATION OF ALL POSITIONS EXCEPT FOR THE CEO. THE CEO'S COMPENSATION PACKAGE IS REVIEWED AND APPROVED INITIALLY BY THE COMPENSATION COMMITTEE AND THEN GOES TO THE EXECUTIVE COMMITTEE FOR FINAL APPROVAL. THE COMPENSATION COMMITTEE CONTEMPORANEOUSLY AND ADEQUATELY DOCUMENTS THE BASIS FOR ITS DETERMINATION AND RECOMMENDATION TO THE EXECUTIVE COMMITTEE. IF APPROVED BY THE EXECUTIVE COMMITTEE, THE CEO COMPENSATION PACKAGE IS THEN IMPLEMENTED AND SUCH DOCUMENTATION IS KEPT IN THE WRITTEN AND ELECTRONIC RECORDS OF THE BOARD OF TRUSTEES. THE PROCESS WAS LAST COMPLETED ON AUGUST 26, 2020 FOR THE FOLLOWING POSITIONS: 1) PRESIDENT 2) CAO/CFO 3) VP BUSINESS DEVELOPMENT 4) VP PHILANTHROPY 5) SVP DRUG DISCOVERY & DEVELOPMENT 6) PROGRAM DIRECTOR/PROFESSOR 7) CANCER CENTER DIRECTOR/PROFESSOR 8) INFECTIOUS & INFLAMMATORY DISEASE CENTER DIRECTOR/PROFESSOR FORM 990, PART VI, LINE 19 PROCESS FOR MAKING DOCUMENTS AVAILABLE TO THE PUBLIC DOCUMENTS ARE AVAILABLE UPON REQUEST.